Circulation reports最新文献

Occupational Therapy for Patients With Cardiovascular Disease　- A Systematic Review. 心血管疾病患者的职业治疗-系统综述。

Circulation reports Pub Date : 2025-05-21 eCollection Date: 2025-06-10 DOI: 10.1253/circrep.CR-24-0162

Tomonori Takeda, Daichi Tsukakoshi, Atsuhiro Tsubaki, Shuhei Yamamoto

{"title":"Occupational Therapy for Patients With Cardiovascular Disease　- A Systematic Review.","authors":"Tomonori Takeda, Daichi Tsukakoshi, Atsuhiro Tsubaki, Shuhei Yamamoto","doi":"10.1253/circrep.CR-24-0162","DOIUrl":"10.1253/circrep.CR-24-0162","url":null,"abstract":"Background: The prevalence of cardiovascular diseases (CVD) is high worldwide. Occupational therapy (OT) allows individuals to participate in activities of daily living (ADLs) and improves their quality of life. However, whether OT improves health-related quality of life (HRQOL), ADLs, fatigue, occupational performance, rehospitalization, and mortality in patients with CVD remains unclear. This study aimed to determine whether OT improves HRQOL, ADLs, fatigue, occupational performance, rehospitalization, and mortality in patients with CVD using a systematic review and meta-analysis.Methods and results: A literature search of 3 databases in October 2024 yielded 4 RCTs on OT in CVD patients. Two trials (n=208) assessed HRQOL, while 2 others (n=220) examined ADLs. One trial (n=23) evaluated fatigue and occupational performance, and another (n=93) assessed rehospitalization and mortality. Due to insufficient data on HRQOL and ADL improvement in 1 trial, a meta-analysis was not feasible. Similarly, a meta-analysis of fatigue, occupational performance, rehospitalization, and mortality could not be performed due to the limited number of studies.Conclusions: The results showed no clear evidence that OT improves HRQOL or ADLs in patients with CVD.","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 6","pages":"395-402"},"PeriodicalIF":0.0,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144268330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Profile and Prognosis of Patients With Acute Decompensated Heart Failure Who Met the Obesity-Related Eligibility for Subcutaneous Semaglutide　- Findings From the CURE-HF Registry. 符合肥胖相关条件的急性失代偿性心力衰竭患者的临床概况和预后——来自CURE-HF登记的发现

Circulation reports Pub Date : 2025-05-16 eCollection Date: 2025-06-10 DOI: 10.1253/circrep.CR-25-0041

Ken Nishikawa, Masatoshi Minamisawa, Koji Yoshie, Sho Suzuki, Kiu Tanaka, Yukari Okuma, Kazuhiro Kimura, Yasushi Ueki, Yasutaka Oguchi, Tamon Kato, Tatsuya Saigusa, Soichiro Ebisawa, Ayako Okada, Hirohiko Motoki, Koichiro Kuwahara

{"title":"Clinical Profile and Prognosis of Patients With Acute Decompensated Heart Failure Who Met the Obesity-Related Eligibility for Subcutaneous Semaglutide　- Findings From the CURE-HF Registry.","authors":"Ken Nishikawa, Masatoshi Minamisawa, Koji Yoshie, Sho Suzuki, Kiu Tanaka, Yukari Okuma, Kazuhiro Kimura, Yasushi Ueki, Yasutaka Oguchi, Tamon Kato, Tatsuya Saigusa, Soichiro Ebisawa, Ayako Okada, Hirohiko Motoki, Koichiro Kuwahara","doi":"10.1253/circrep.CR-25-0041","DOIUrl":"10.1253/circrep.CR-25-0041","url":null,"abstract":"Background: Obesity is well-established risk factor of heart failure (HF); however, \"obesity paradox\" has been described in symptomatic HF patients. The STEP-HFpEF study suggested that once-weekly subcutaneous semaglutide might improve outcomes in patients with obesity-related HF. We explored the prevalence of obesity-related eligibility for semaglutide treatment among patients with acute decompensated heart failure (ADHF) and evaluated their prognoses.Methods and results: We analyzed data from 1,017 ADHF patients (median, 81 years; 44.2% female) enrolled in the CURE-HF registry. We assessed prevalence of obesity-related eligibility for semaglutide administration and examined the association between this eligibility and all-cause death over a median follow-up of 2.7 years. There were 73 patients (7.2%) who were semaglutide-eligible and they had a higher proportion of diabetes mellitus than patients who were semaglutide non-eligible (64.4% vs. 26.4%, P<0.001). Kaplan-Meier analysis indicated that semaglutide-eligible patients had a significantly lower all-cause mortality rate than non-eligible patients (log-rank P=0.005). After adjustment for demographic characteristics, there was no significant difference in mortality rate between the 2 groups (adjusted hazard ratio 0.63, 95% confidence interval (CI) 0.34-1.17, P=0.14). In the propensity score-matched cohort, we did not observe a significant difference in mortality rate (log-rank, P=0.79).Conclusions: Almost 7.2% of the ADHF patients were semaglutide-eligible. Our findings did not affirm the \"obesity paradox\" in semaglutide-eligible HF patients after adjusting for demographic factors.","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 6","pages":"463-472"},"PeriodicalIF":0.0,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12149744/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144268325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Influence of the Presence of Other People on Performing Rescue Actions in Emergency Situations　- A Questionnaire Survey. 他人在场对紧急情况下救援行动的影响-问卷调查。

Circulation reports Pub Date : 2025-05-14 eCollection Date: 2025-06-10 DOI: 10.1253/circrep.CR-24-0166

Haruka Shida, Chika Nishiyama, Satoe Okabayashi, Yosuke Yamamoto, Tomonari Shimamoto, Takashi Kawamura, Tetsuya Sakamoto, Taku Iwami

{"title":"Influence of the Presence of Other People on Performing Rescue Actions in Emergency Situations　- A Questionnaire Survey.","authors":"Haruka Shida, Chika Nishiyama, Satoe Okabayashi, Yosuke Yamamoto, Tomonari Shimamoto, Takashi Kawamura, Tetsuya Sakamoto, Taku Iwami","doi":"10.1253/circrep.CR-24-0166","DOIUrl":"10.1253/circrep.CR-24-0166","url":null,"abstract":"Background: Because bystander performance of cardiopulmonary resuscitation in out-of-hospital cardiac arrest cases is influenced by the number of rescuers/bystanders, we assessed the relationship between the presence of other people and performance of rescue actions in an actual emergency situation.Methods and results: A cross-sectional study was performed using data from an anonymous self-administered questionnaire-based survey that included laypersons who had encountered emergency situations during the past 5 years. Based on their responses related to the presence of other people, laypersons were divided into 2 groups: \"single-bystander\" (absence of others) and \"multiple-bystanders\" (presence of others). The primary outcome was any rescue action(s) performed by laypersons during an emergency. A total of 1,219 laypersons were eligible for our analysis; 69 (5.7%) encountered emergencies in which others were absent (single-bystander group) and 1,150 (94.3%) encountered emergencies in which others were present (multiple-bystanders group). The proportion of laypersons who performed any rescue actions was 95.7% in the single-bystander group and 73.8% in the multiple-bystanders group.Conclusions: The proportion of laypersons who performed any rescue actions was lower when other people were present compared with when they were absent.","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 6","pages":"419-425"},"PeriodicalIF":0.0,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148356/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144268328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rationale and Protocol of the Registry for Contemporary Medical Management of Chronic Heart Failure With Mildly Reduced and Preserved Ejection Fraction　- The PARACLETE Study. 慢性心力衰竭伴射血分数轻度降低和保留的当代医学管理登记的基本原理和方案- PARACLETE研究

Circulation reports Pub Date : 2025-05-14 eCollection Date: 2025-06-10 DOI: 10.1253/circrep.CR-24-0138

Tomoya Ueda, Koichiro Kuwahara, Shinya Hiramitsu, Katsuya Onishi, Dai Yumino, Ayako Seno, Kenji Shiino, Maki Nogi, Masahiro Isogawa, Atsuhiko Kawamoto, Masato Kasahara, Shungo Hikoso, Yoshihiko Saito

{"title":"Rationale and Protocol of the Registry for Contemporary Medical Management of Chronic Heart Failure With Mildly Reduced and Preserved Ejection Fraction　- The PARACLETE Study.","authors":"Tomoya Ueda, Koichiro Kuwahara, Shinya Hiramitsu, Katsuya Onishi, Dai Yumino, Ayako Seno, Kenji Shiino, Maki Nogi, Masahiro Isogawa, Atsuhiko Kawamoto, Masato Kasahara, Shungo Hikoso, Yoshihiko Saito","doi":"10.1253/circrep.CR-24-0138","DOIUrl":"10.1253/circrep.CR-24-0138","url":null,"abstract":"Background: There is recent evidence for the medical treatment of heart failure (HF) with mildly reduced ejection fraction (EF) and preserved EF (HFmrEF/HFpEF). However, in real-world settings, information on how cardiologists treat patients with HFmrEF/HFpEF, especially those with chronic, mild, and stable HF or newly diagnosed HF, is lacking. In other words, we do not know when cardiologists should start and intensify medical treatment, which drugs they should choose, or why. To answer these questions, we will conduct an observational study of HFmrEF/HFpEF. Here, we describe the rationale and protocol of this observational study.Methods and results: This study will explore the therapeutic status of approximately 4,200 patients who were diagnosed or newly diagnosed with chronic HFmrEF/HFpEF (LVEF >40%) at approximately 70 cardiology clinics and hospitals. After enrolment, physicians will check whether the current medical therapy is appropriate for each patient and initiate or intensify HF medical therapy appropriately. The primary endpoints will be: (1) the proportion of patients within the categories of reasons for changing prescriptions at visit 1 of HF medical therapy and (2) a composite of unexpected HF hospitalization and all-cause death in a 2-year follow-up.Conclusions: This registry will uniquely confirm the current treatment status of patients with HFmrEF/HFpEF in real-world settings.","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 6","pages":"491-496"},"PeriodicalIF":0.0,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148361/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144268333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Relationship Between Health-Related Quality of Life and Frailty in Older Patients Participating in Early Phase II Cardiac Rehabilitation. 参与早期二期心脏康复的老年患者健康相关生活质量与衰弱的关系

Circulation reports Pub Date : 2025-05-13 eCollection Date: 2025-06-10 DOI: 10.1253/circrep.CR-24-0180

Jianying Xu, Miho Nishitani-Yokoyama, Hiroki Kasuya, Mayumi Yamashita, Yusei Sato, Junya Nishimura, Mai Iida, Kei Fujiwara, Mitsuhiro Kunimoto, Yurina Sugita-Yamaguchi, Taisuke Nakade, Minoru Tabata, Kazunori Shimada, Hiroyuki Daida, Tohru Minamino

{"title":"The Relationship Between Health-Related Quality of Life and Frailty in Older Patients Participating in Early Phase II Cardiac Rehabilitation.","authors":"Jianying Xu, Miho Nishitani-Yokoyama, Hiroki Kasuya, Mayumi Yamashita, Yusei Sato, Junya Nishimura, Mai Iida, Kei Fujiwara, Mitsuhiro Kunimoto, Yurina Sugita-Yamaguchi, Taisuke Nakade, Minoru Tabata, Kazunori Shimada, Hiroyuki Daida, Tohru Minamino","doi":"10.1253/circrep.CR-24-0180","DOIUrl":"10.1253/circrep.CR-24-0180","url":null,"abstract":"Background: Frailty is a significant prognostic risk factor for cardiovascular disease and it can lead to poor quality of life due to malnutrition, fatigue, and reduced physical activity. However, few studies have investigated how frailty affects older patients participating in cardiac rehabilitation (CR) on health-related quality of life (HRQoL).Methods and results: Between November 2015 and December 2016 at Juntendo University Hospital, 217 patients (mean age 74.6±5.8 years; males 67%) participated in CR. Patients completed self-evaluations using the 36-item Short Form Survey (SF-36) and the Kihon Checklist (KCL) at the baseline of CR. The patients were divided into 3 groups: frailty group (n=81; 37%); pre-frailty group (n=71; 33%); and non-frailty group (n=65; 30%). Based on the KCL findings, we compared demographics, clinical measures, and SF-36 scores among the 3 groups. Sex, body mass index, 6-min walking distance, hemoglobin level, and low-density lipoprotein cholesterol differed significantly among the 3 groups. All SF-36 items also showed significant group differences; the frailty group scored lower than the other 2 groups on the physical component summary and mental component summary (MCS). Furthermore, the frailty group had a lower MCS score than the average Japanese age level.Conclusions: Frail older patients undergoing CR experience significant deterioration in both physical and mental dimensions of HRQoL.","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 6","pages":"411-418"},"PeriodicalIF":0.0,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144268336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Low Arterial Stiffness by Pulse Wave Analysis and Aortic Diseases. 脉搏波分析与主动脉疾病的低动脉硬度分析。

Circulation reports Pub Date : 2025-04-29 eCollection Date: 2025-06-10 DOI: 10.1253/circrep.CR-25-0043

Akira Sakamoto, Yutaka Nakamura, Nobuyuki Kagiyama, Eiichiro Sato, Wataru Fujita, Tomohiro Kaneko, Tohru Minamino

{"title":"Low Arterial Stiffness by Pulse Wave Analysis and Aortic Diseases.","authors":"Akira Sakamoto, Yutaka Nakamura, Nobuyuki Kagiyama, Eiichiro Sato, Wataru Fujita, Tomohiro Kaneko, Tohru Minamino","doi":"10.1253/circrep.CR-25-0043","DOIUrl":"10.1253/circrep.CR-25-0043","url":null,"abstract":"Background: The cardio-ankle vascular index (CAVI) is an important marker of arterial stiffness, providing a blood pressure-independent assessment of vascular function. However, the clinical significance of low CAVI values remains unclear. Some connective tissue diseases are associated with aortic diseases due to intrinsic arterial wall abnormalities and may exhibit low CAVI values. This study aimed to investigate whether low CAVI is associated with these connective tissue diseases and succeeding aortic diseases.Methods and results: This was a single-center, retrospective observational study conducted at Juntendo University Hospital. A total of 17,364 patients aged 20-80 years who underwent arterial stiffness analysis using CAVI were included. Low CAVI was defined as the lowest 2.5 percentile within each sex- and age-specific distribution. The prevalences of aortic diseases (dissection and/or aneurysm) and Marfan syndrome were similar between the between the low CAVI and normal CAVI groups (aortic disease, 3.99% vs. 3.99%, P>0.99; Marfan syndrome, 0.04% vs. 0.07%, P>0.99, for the low and normal CAVI group, respectively).Conclusions: This study found no evidence that patients with low CAVI had an increased prevalence of aortic dissection, aortic aneurysm, or Marfan syndrome. Further studies are needed to clarify the clinical implications of low CAVI in vascular diseases.","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 6","pages":"481-485"},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148350/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144268329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An Aspirin-Free Strategy for Patients Undergoing Staged Percutaneous Coronary Intervention　- A Subgroup Analysis of the STOPDAPT-3 Trial. 分期经皮冠状动脉介入治疗患者的无阿司匹林策略- stopdpt -3试验的亚组分析

Circulation reports Pub Date : 2025-04-29 eCollection Date: 2025-06-10 DOI: 10.1253/circrep.CR-25-0026

Ko Yamamoto, Masahiro Natsuaki, Hirotoshi Watanabe, Takeshi Morimoto, Yuki Obayashi, Ryusuke Nishikawa, Tomoya Kimura, Kenji Ando, Satoru Suwa, Tsuyoshi Isawa, Hiroyuki Takenaka, Tetsuya Ishikawa, Takafumi Yokomatsu, Toshiya Chinen, Tatsuki Doijiri, Ken Kozuma, Yasunori Nishida, Koji Yamaguchi, Hideki Kitahara, Mitsunori Ishino, Koh Ono, Takeshi Kimura

{"title":"An Aspirin-Free Strategy for Patients Undergoing Staged Percutaneous Coronary Intervention　- A Subgroup Analysis of the STOPDAPT-3 Trial.","authors":"Ko Yamamoto, Masahiro Natsuaki, Hirotoshi Watanabe, Takeshi Morimoto, Yuki Obayashi, Ryusuke Nishikawa, Tomoya Kimura, Kenji Ando, Satoru Suwa, Tsuyoshi Isawa, Hiroyuki Takenaka, Tetsuya Ishikawa, Takafumi Yokomatsu, Toshiya Chinen, Tatsuki Doijiri, Ken Kozuma, Yasunori Nishida, Koji Yamaguchi, Hideki Kitahara, Mitsunori Ishino, Koh Ono, Takeshi Kimura","doi":"10.1253/circrep.CR-25-0026","DOIUrl":"10.1253/circrep.CR-25-0026","url":null,"abstract":"Background: No previous studies have evaluated the effect of an aspirin-free strategy for patients undergoing staged percutaneous coronary intervention (PCI).Methods and results: We conducted a post hoc subgroup analysis in patients undergoing staged PCI within 1 month in STOPDAPT-3 (n=6,002), which randomly compared prasugrel monotherapy with dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome or high bleeding risk. The co-primary endpoints were major bleeding (Bleeding Academic Research Consortium 3 or 5) and cardiovascular events (a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or stroke) at 1 month. There were 814 patients undergoing staged PCI within 1 month (no-aspirin group, n=401; DAPT group, n=413). The median interval from randomization to the first staged PCI was 8 (interquartile range 5-13) days. More than 90% of the patients received assigned antiplatelet agents at all staged PCI procedures. The effect of no-aspirin relative to DAPT was not different for the co-primary bleeding (3.74% vs. 1.94%; HR 1.94; 95% CI 0.82-4.57) and cardiovascular (3.49% vs. 2.42%; HR 1.44; 95% CI 0.64-3.25) endpoints. The no-aspirin group compared with the DAPT group had a numerically higher incidence of the co-primary cardiovascular endpoint, which occurred after the first staged PCI procedure (2.49% vs. 1.21%; HR 2.07; 95% CI 0.71-6.05).Conclusions: An aspirin-free prasugrel monotherapy relative to DAPT had numerically higher risks of cardiovascular and major bleeding events in patients undergoing staged PCI at 1 month.","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 6","pages":"451-462"},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148353/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144268324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic Impact of Sustained Reduction of N-Terminal Pro-B-Type Natriuretic Peptide After Initiating Sacubitril/Valsartan　- Insights From the REVIEW-HF Registry. 开始服用沙克比利/缬沙坦后n端前b型利钠肽持续减少对预后的影响——来自REVIEW-HF注册的见解

Circulation reports Pub Date : 2025-04-22 eCollection Date: 2025-06-10 DOI: 10.1253/circrep.CR-25-0029

Yu Takigami, Shunsuke Ishii, Yuichiro Iida, Yuki Ikeda, Takeru Nabeta, Jun Oikawa, Takahito Nasu, Koshiro Kanaoka, Nobuyuki Kagiyama, Keisuke Kida, Wataru Fujimoto, Atsushi Kikuchi, Takeshi Ijichi, Tatsuhiro Shibata, Junya Ako, Shingo Matsumoto

{"title":"Prognostic Impact of Sustained Reduction of N-Terminal Pro-B-Type Natriuretic Peptide After Initiating Sacubitril/Valsartan　- Insights From the REVIEW-HF Registry.","authors":"Yu Takigami, Shunsuke Ishii, Yuichiro Iida, Yuki Ikeda, Takeru Nabeta, Jun Oikawa, Takahito Nasu, Koshiro Kanaoka, Nobuyuki Kagiyama, Keisuke Kida, Wataru Fujimoto, Atsushi Kikuchi, Takeshi Ijichi, Tatsuhiro Shibata, Junya Ako, Shingo Matsumoto","doi":"10.1253/circrep.CR-25-0029","DOIUrl":"10.1253/circrep.CR-25-0029","url":null,"abstract":"Background: Serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) values after initiating sacubitril/valsartan (Sac/Val) are considered a favorable prognostic factor in patients with heart failure (HF). However the relationship between the trajectory of repeated NT-proBNP measurements and cardiovascular events after Sac/Val remains uncertain.Methods and results: A Japanese nationwide multicenter study enrolled 995 patients who were prescribed Sac/Val from August 2020 to August 2021. Of them, 434 patients who had a complete set of NT-proBNP measurements were divided into 3 groups: sustained-responder group (n=129), with ≥10% reduction in NT-proBNP at 1 month and further ≥10% reduction at 3 months; transient-responder group (n=161), with ≥10% reduction at 1 month but not at 3 months; and non-responder group (n=144), without ≥10% reduction at 1 month. There were no significant differences in the mean Sac/Val dose at each measurement point among the 3 groups. During a median follow-up of 456 (interquartile range: 371-549) days, the primary endpoint, which was either cardiovascular death or hospitalization for HF, occurred in 78 patients. Kaplan-Meier analysis revealed that the sustained-responder group had a significantly higher event-free survival rate among the 3 groups (Log-rank P<0.001).Conclusions: Repeated NT-proBNP monitoring and the pattern of the NT-proBNP trajectory after Sac/Val may be helpful in optimizing HF therapy and understanding the prognosis of HF.","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 6","pages":"433-441"},"PeriodicalIF":0.0,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148359/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144268332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of Tailored Multidisciplinary Cardiac Rehabilitation on Patients With Cardiovascular Diseases and Multimorbidity in Convalescent Rehabilitation Hospitals in Japan　- A Multicenter, Prospective Observational Study. 量身定制的多学科心脏康复对日本康复医院心血管疾病和多种疾病患者的影响——一项多中心、前瞻性观察研究

Circulation reports Pub Date : 2025-04-22 eCollection Date: 2025-06-10 DOI: 10.1253/circrep.CR-24-0137

Ryo Miyazawa, Yoshitaka Iso, Satoshi Yamamoto, Tomohiro Matsuo, Tomoyuki Morisawa, Tetsuya Takahashi, Shigeru Makita, Shigeru Fujimoto

{"title":"Impact of Tailored Multidisciplinary Cardiac Rehabilitation on Patients With Cardiovascular Diseases and Multimorbidity in Convalescent Rehabilitation Hospitals in Japan　- A Multicenter, Prospective Observational Study.","authors":"Ryo Miyazawa, Yoshitaka Iso, Satoshi Yamamoto, Tomohiro Matsuo, Tomoyuki Morisawa, Tetsuya Takahashi, Shigeru Makita, Shigeru Fujimoto","doi":"10.1253/circrep.CR-24-0137","DOIUrl":"10.1253/circrep.CR-24-0137","url":null,"abstract":"Background: Data on cardiac rehabilitation (CR) outcomes in patients with cardiovascular disease (CVD), frailty, and multimorbidity in post-acute settings are limited. This study aimed to evaluate the feasibility and efficacy of individualized, multidisciplinary CR in convalescent rehabilitation hospitals (cRHs).Methods and results: This multicenter, prospective, observational study included 72 consecutive patients transferred from acute care hospitals. Personalized CR programs were implemented in cRHs. Primary outcomes were changes in the Barthel Index (BI) and functional independence measure (FIM) scores. Secondary outcomes included assessments of physical and cognitive function, and nutritional status. Mean participant age was 78.6±11.8 years. Prior to admission, 51.4% experienced acute decompensated heart failure (ADHF). The average length of stay was 59.5±39.2 days. BI and FIM scores improved from admission to discharge. The following parameters improved: Short Physical Performance Battery, knee extensor strength, comfortable gait speed, 6-min walk distance, New York Heart Association classification, and cognitive function (Mini-Mental State Examination). Discharge dispositions included 53 (73.6%) home discharges, and 19 (26.4%) outpatient CR post-discharges. Patients with post-ADHF and patients with other conditions both showed functional improvements, but ∆BI and ∆FIM were lower in the post-ADHF group.Conclusions: Tailored multidisciplinary CR in cRHs effectively improves daily living activities and physical and cognitive outcomes in patients with CVD with complex conditions. Expanded use of these hospitals may help address clinical challenges.","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 6","pages":"403-410"},"PeriodicalIF":0.0,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148360/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144268327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-World Clinical Impact of Tafamidis on Transthyretin Amyloid Cardiomyopathy　- A Decade of Experience From a Community-Based Hospital (2015-2024). 他法非地对转甲状腺素淀粉样蛋白心肌病的临床影响——来自社区医院的十年经验（2015-2024）。

Circulation reports Pub Date : 2025-04-18 eCollection Date: 2025-06-10 DOI: 10.1253/circrep.CR-25-0031

Toru Kubota, Seiya Kato, Daisuke Nagatomo, Akihito Ishikita, Masatsugu Nozoe, Nobuhiro Suematsu

{"title":"Real-World Clinical Impact of Tafamidis on Transthyretin Amyloid Cardiomyopathy　- A Decade of Experience From a Community-Based Hospital (2015-2024).","authors":"Toru Kubota, Seiya Kato, Daisuke Nagatomo, Akihito Ishikita, Masatsugu Nozoe, Nobuhiro Suematsu","doi":"10.1253/circrep.CR-25-0031","DOIUrl":"10.1253/circrep.CR-25-0031","url":null,"abstract":"Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is increasingly recognized as a major cause of heart failure in elderly patients with left ventricular hypertrophy. Although tafamidis was approved in 2019 following the ATTR-ACT study, its real-world survival impact in community settings remains unclear.Methods and results: This retrospective study analyzed 117 patients diagnosed with ATTR-CM at a single center from 2015 to 2024, with 75 receiving tafamidis and 42 untreated. Among the 83 patients who underwent genetic testing, all had the wild-type genotype. ATTR-CM diagnoses increased significantly after the advent of 99 mTc-pyrophosphate scintigraphy and tafamidis. Kaplan-Meier analysis showed significantly longer survival in tafamidis-treated patients. Multivariate analysis identified New York Heart Association (NYHA) functional class, left ventricular wall thickness, N-terminal prohormone of brain natriuretic peptide (NT-proBNP) levels, and tafamidis treatment as independent survival predictors. Tafamidis treatment was associated with significantly improved survival in patients who were younger, had a less advanced NYHA functional class, and lower levels of NT-proBNP and troponin T. In contrast, its survival benefits were marginal in patients with older age, higher NYHA functional class, elevated NT-proBNP levels, and increased troponin T levels.Conclusions: In this real-world cohort, tafamidis treatment was significantly associated with better survival in ATTR-CM patients, particularly when initiated in the early stage. Therefore, early detection and timely initiation of treatment are critical for optimizing clinical outcomes in this increasingly recognized condition.","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 6","pages":"442-450"},"PeriodicalIF":0.0,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148351/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144268334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0